X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15077) 15077
Newsletter (235) 235
Book Chapter (21) 21
Magazine Article (14) 14
Newspaper Article (9) 9
Publication (6) 6
Conference Proceeding (5) 5
Book Review (4) 4
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10605) 10605
male (7452) 7452
animals (5842) 5842
female (5568) 5568
pyrimidines - administration & dosage (5169) 5169
pyrimidines - therapeutic use (4569) 4569
pyrimidines - pharmacology (4335) 4335
middle aged (3710) 3710
adult (3357) 3357
oncology (3054) 3054
imatinib mesylate (2974) 2974
aged (2725) 2725
pharmacology & pharmacy (2702) 2702
mice (2500) 2500
benzamides (2369) 2369
rats (2332) 2332
pyrimidines - adverse effects (2291) 2291
treatment outcome (2219) 2219
pyrimidines (2018) 2018
dose-response relationship, drug (1676) 1676
cancer (1628) 1628
hematology (1507) 1507
piperazines - administration & dosage (1507) 1507
piperazines - therapeutic use (1499) 1499
antineoplastic agents - therapeutic use (1493) 1493
pyrimidines - pharmacokinetics (1372) 1372
research (1329) 1329
administration, oral (1327) 1327
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1258) 1258
analysis (1203) 1203
care and treatment (1186) 1186
antineoplastic agents - administration & dosage (1153) 1153
imatinib (1153) 1153
therapy (1089) 1089
drug therapy (1057) 1057
protein kinase inhibitors - therapeutic use (1019) 1019
cell line, tumor (995) 995
time factors (990) 990
voriconazole (974) 974
adolescent (948) 948
medicine & public health (918) 918
pharmacokinetics (901) 901
aged, 80 and over (895) 895
antineoplastic combined chemotherapy protocols - therapeutic use (879) 879
rosuvastatin calcium (872) 872
expression (866) 866
protein kinase inhibitors - administration & dosage (862) 862
young adult (821) 821
chemotherapy (820) 820
drug administration schedule (818) 818
sulfonamides - administration & dosage (816) 816
rats, sprague-dawley (800) 800
neurosciences (794) 794
piperazines - pharmacology (793) 793
chronic myelogenous leukemia (777) 777
sulfonamides - therapeutic use (775) 775
health aspects (768) 768
chronic myeloid-leukemia (764) 764
disease models, animal (756) 756
biochemistry & molecular biology (747) 747
protein-tyrosine kinases - antagonists & inhibitors (743) 743
antineoplastic agents - pharmacology (719) 719
protein kinase inhibitors - pharmacology (718) 718
apoptosis (709) 709
dosage and administration (704) 704
pyrimidines - chemistry (697) 697
efficacy (695) 695
dasatinib (692) 692
safety (685) 685
antineoplastic agents - adverse effects (682) 682
piperazines - adverse effects (674) 674
abridged index medicus (665) 665
leukemia (662) 662
chronic myeloid leukemia (659) 659
mutation (648) 648
tumors (621) 621
apoptosis - drug effects (613) 613
drug therapy, combination (612) 612
antineoplastic agents (599) 599
pyrimidines - blood (593) 593
in-vitro (589) 589
double-blind method (587) 587
activation (582) 582
cell proliferation - drug effects (576) 576
kinases (574) 574
clinical trials (569) 569
rats, wistar (565) 565
triazoles - administration & dosage (563) 563
cell biology (561) 561
proteins (559) 559
signal transduction - drug effects (555) 555
cells (544) 544
physiological aspects (541) 541
chemistry, medicinal (539) 539
antimitotic agents (538) 538
mice, inbred c57bl (530) 530
drug interactions (525) 525
inhibition (521) 521
pharmacology/toxicology (519) 519
risk factors (518) 518
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14753) 14753
Japanese (300) 300
German (155) 155
Russian (84) 84
French (78) 78
Chinese (48) 48
Spanish (43) 43
Italian (29) 29
Polish (17) 17
Hungarian (13) 13
Czech (7) 7
Danish (7) 7
Dutch (7) 7
Ukrainian (6) 6
Portuguese (5) 5
Swedish (5) 5
Hebrew (4) 4
Norwegian (4) 4
Turkish (3) 3
Romanian (2) 2
Bulgarian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
...). However, the potential for drug interactions with co‐administration of GSK2248761 and other antiretroviral medications or supportive medications is not known... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent... 
Chemo-gynecology | Molecular Dx | Gynecol-med | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | gynecol-med | BEVACIZUMAB | molecular Dx | COMBINATION | CHEMOTHERAPY | PACLITAXEL | PHASE-III TRIAL | THERAPY | ONCOLOGY | DOUBLE-BLIND | PROGRESSION | chemo-gynecology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Blood, ISSN 1528-0020, 2013, Volume 122, Issue 7, pp. 1214 - 1221
Detection of MRD by real-time quantitative PCR and flow cytometry is an important predictor of outcome in patients with Ph+ ALL. 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Lymphoid Neoplasia
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Erythrocyte sedimentation rate | Drug therapy | Pharmaceuticals | Cancer
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
by Fleischmann, Roy and Mysler, Eduardo and Hall, Stephen and Kivitz, Alan J and Moots, Robert J and Luo, Zhen and DeMasi, Ryan and Soma, Koshika and Zhang, Richard and Takiya, Liza and Tatulych, Svitlana and Mojcik, Christopher and Krishnaswami, Sriram and Menon, Sujatha and Smolen, Josef S and Adams, Luthando and Ally, Mahmood M and du Plooy, Maria C and Louw, Ingrid C and Nayiager, Savithree and Nel, Christoffel B and Nel, Debra and Reuter, Helmuth and Soloman, Ahmed S and Spargo, Catherine E and Rischmueller, Maureen and Sharma, Shunil D and Will, Robert K and Youssef, Peter P and Arroyo, Caroline and Baes, Rosario P and Dulos, Roger B and Hao, Llewellyn T and Lanzon, Allan E and Lichauco, Juan Javier T and Mangubat, Jill H and Ramiterre, Edgar B and Reyes, Bernadette Heizel M and Tan, Perry P and Choe, Jung-Yoon and Kang, Young Mo and Kwon, Seong Ryul and Lee, Sang-Heon and Lee, Shin-Seok and Yoo, Dae-Hyun and Lin, Hsiao-Yi and Luo, Shue-Fen and Tsai, Shih-Tzu and Tsai, Wen-Chan and Tseng, Jui-Cheng and Wei, Cheng-Chung C and Asavatanabodee, Paijit and Nantiruj, Kanokrat and Nilganuwong, Surasak and Uea-Areewongsa, Parichat and Majstorovic, Ljubinka Bozic and Bacic, Suada Mulic and Batalov, Anastas Z and Georgieva-Slavcheva, Gabriela and Mihailova, Mariyana and Nikolov, Nikolay G and Penev, Dimitar P and Spasov, Yuliy A and Stanimirova, Krasimira and Todorov, Stoyan and Toncheva, Antoaneta R and Yordanova, Nadezhda and Mosterova, Zdenka and Novosad, Libor and Prochazkova, Leona and Stehlikova, Helena and Stejfova, Zuzana and Kiseleva, Natalia and Pank, Lea and Savi, Triin and Alexandra, Balbir-Gurman and Amital, Howard and Mevorach, Dror and Rosner, Itzhak A and Mihailova, Anna and Stumbra-Stumberga, Evija and Basijokiene, Vida and Lietuvininkiene, Virginija and Unikiene, Dalia and Brzezicki, Jan and Dudek, Anna M and Glowacka-Kulesz, Maria B and Grabowicz-Wasko, Barbara and Hajduk-Kubacka, Sabina and Hilt, Joanna and Hrycaj, Pawel and Jeka, Slawomir and Kolasa, Renata and Krogulec, Marek and Mastalerz, Hanna and Olak-Popko, Anna and Owczarek, Elzbieta and Ruzga, Zofia and Walczak, Alina and Ancuta, Codrina I and ... and ORAL Strategy investigators and ORAL Strategy Investigators
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Evidence-based medicine | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article